Relatively, under PD-1 immunotherapy, melanoma patients might have the minimum risk of treatment-associated pneumonitis, while NSCLC and RCC patients should be rather cautious for the appearance of pneumonitis. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.